Highlights from day 2
On the second day in Copenhagen, we asked Dr Koen Deschepper (Vitaz – Oost Vlaanderen) to summarize the most exciting presentations of the proferred paper session.
He first discussed the 3-year update of the CheckMate 816 study of neoadjuvant nivolumab in combination with platinum-doublet chemotherapy for resectable NSCLC. A second highly interesting study was the EMPOWER LUNG 3 study in NSCLC, in which longer follow-up results comparing cemiplimab plus chemotherapy versus chemotherapy alone were presented. The RESILIENT study compared liposomal irinotecan with topotecan in adults with relapsed SCLC.
With the support of:
No Comment! Be the first one.